Skip to main content
. 2020 Aug 7;1(4):100081. doi: 10.1016/j.jtocrr.2020.100081

Figure 1.

Figure 1

Chronology of treatment, response, molecular pathology, and imaging. Images A and F reveal the pretreatment baseline scans with extensive bilateral miliary metastases in the lung; B and G, the 4-week post-poziotinib scans; C, the flare 3 weeks after poziotinib discontinuation; D, the treatment response after reinitiation of poziotinib on the EAP; E, the second flare 2 weeks after discontinuation of poziotinib EAP; H, the development of a new RUL nodule 5 months and 19 days after 16 mg PO daily of poziotinib; I, progression of the right lung disease 12 weeks after 12 mg PO daily of poziotinib. CGP, comprehensive genomic profiling; CT, computed tomography; D/C, discontinued; EAP, expanded access protocol; MRI, magnetic resonance imaging; PD, progressive disease; PO, orally; PR, partial response; RUL, right upper lobe.